| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ArriVent Biopharma, Inc. | General Counsel | Common Stock | 7.39K | $27K | $3.65 | Jan 25, 2024 | Direct |
| Aeglea BioTherapeutics, Inc. | General Counsel | Employee Stock Option (right to buy) | 500K | Feb 23, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| AVBP | ArriVent Biopharma, Inc. | Jan 25, 2024 | 0 | $0 | 3 | Jan 25, 2024 | General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Feb 23, 2023 | 1 | $0 | 4 | Feb 24, 2023 | General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Aug 23, 2022 | 1 | $0 | 4 | Aug 25, 2022 | Interim CEO & General Counsel |
| AGLE | Aeglea BioTherapeutics, Inc. | Aug 23, 2022 | 0 | $0 | 3 | Aug 25, 2022 | Interim CEO & General Counsel |